Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Internal Medicine
•
Rheumatology
•
Inflammatory Bowel Disease
•
General Rheumatology
•
Gastroenterology
•
TNF inhibitor
•
Immunosuppression
•
Anaphylaxis
In patients with history of anaphylaxis to a TNF inhibitor, are you comfortable trying an alternative TNF inhibitor?
Related Questions
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
How would you approach the treatment of an SLE patient with refractory mucocutaneous ulcerations and lichenoid skin eruption despite treatment with MMF, Aza, Benlysta, Saphnelo, Rituximab, and JAK inhibitors?
How would you manage a patient with highly active ankylosing spondylitis, iritis and Crohn’s, controlled with weekly adalimumab with co-morbid IgG4RD and intolerance of azathioprine due to elevated LFTs?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Have you utilized JAK inhibitors in patients on dialysis?
Do you prefer celecoxib over a nonselective NSAID in patients with chronic kidney disease?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?